Lilly To Pay Utah $24M Over Zyprexa Marketing

By Elaine Meyer

Law360, New York (November 11, 2009, 1:19 PM ET) -- Eli Lilly & Co. will pay Utah $24 million in the latest state settlement over the pharmaceutical giant's alleged off-label marketing of the antipsychotic Zyprexa, state officials said Wednesday.

Utah Attorney General Mark Shurtleff announced that the state reached the settlement after a four-year investigation that found Lilly's sales force illegally promoted the drug for uses not approved by the U.S. Food and Drug Administration and concealed side effects of significant weight gain and obesity.

It is Utah's largest settlement with a pharmaceutical company for unlawful...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles